This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
Kauvery group of hospitals, a leading healthcare chain in Tamil Nadu, has roped in former Indian cricket captain Mahendra Singh Dhoni as its brand ambassador
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Domestic market and developing countries will need doses of Indian vaccines
The company reports revenue growth of 26% and PAT growth of 21% YoY
The group has a total of 320 ANDA approvals
Subscribe To Our Newsletter & Stay Updated
